Rifaximin Predicts the Complications of Decompensated Cirrhosis
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and
increased intestinal permeability all leading to an increase in bacterial translocation and
increased endotoxemia. Rifaximin is an antibiotic that is virtually non-absorbed after oral
administration and exhibits broad spectrum antimicrobial activity against both aerobic and
anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
It has been suggested that oral prophylactic antibiotics or bowel decontamination might
improve long-term outcomes in patients with cirrhosis. The aim of this study was to explore
the suitable dose of rifaximin to alleviate endotoxemia and prevent the complications of
advanced cirrhosis.